Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin’s lymphoma: where we stand

References

• Armitage JO, Fyfe MAE, Lewis J et al. Long term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J. Clin. Oncol.2, 898–902 (1984).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N. Engl. J. Med.328(14), 1002–1006 (1993).
   PubMed Web of Science ®Google Scholar
• Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N. Engl. J. Med.327(19), 1342–1349 (1992).
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Cavallin-Ståhl E et al. CHOP versus MACOP-B in aggressive lymphoma – a Nordic Lymphoma Group randomised trial. Ann. Oncol.10, 1079–1086 (1999).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Österborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol.7, 379–391 (2006).
   PubMed Web of Science ®Google Scholar
• Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin. Oncol.33(3 Suppl. 8), S2–S7 (2006).
   Web of Science ®Google Scholar
• Johnson SA. Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin. Oncol.33(3 Suppl. 8), S22–S27 (2006).
   PubMed Web of Science ®Google Scholar
• Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol.26(22), 3777–3784 (2008).
   PubMed Web of Science ®Google Scholar
• Conley BA, Egorin MJ, Whitacre MT et al. Phase I and pharmacokinetic trial of liposome encapsulated doxorubicin. Cancer Chemother. Pharmacol.33, 107–112 (1993).
   PubMed Web of Science ®Google Scholar
• Cowens JW, Creaven PJ, Greco WR et al. Initial clinical (Phase I) trial of Myocet (doxorubicin encapsulated in liposomes). Cancer Res.53, 2796–2802 (1993).
   PubMed Web of Science ®Google Scholar
• Ostro MJ. Liposomes: from the bench to the marketplace – doxorubicin as an example. In: Liposomes in the Therapy of Infectious Diseases and Cancer. Fidler IJ, Lopez-Berestein G (Eds). Alan Liss, Inc., NY, USA 155–163 (1989).
   Google Scholar
• Mayer LD, Bally MB, Cullis PR et al. Comparison of free and liposome-encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett.53, 183–190 (1990).
   PubMed Web of Science ®Google Scholar
• Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol.19, 1444–1454 (2001).
   PubMed Web of Science ®Google Scholar
• Valero V, Buzdar AU, Theriault RL et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluoracil as first-line therapy in patients with metastatic breast cancer. J. Clin. Oncol.17, 1425–1434 (1999).
   PubMed Web of Science ®Google Scholar
• Mrozek E, Rhoades CA, Allen J, Hade EM, Shapiro CL. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients. Ann. Oncol.16, 1087–1093 (2005).
   PubMed Web of Science ®Google Scholar
• Schmid P, Krocker J, Jehn C et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a Phase II trial. Ann. Oncol.16, 1624–1631 (2005).
   PubMedGoogle Scholar
• Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer94, 25–36 (2002).
   PubMed Web of Science ®Google Scholar
• Chan S, Davidson N, Juozaityte E et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as firstline therapy for metastatic breast cancer. Ann. Oncol.15, 1527–1534 (2004).
   PubMed Web of Science ®Google Scholar
• Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-Cancer Drugs17, 587–594 (2006).
   PubMed Web of Science ®Google Scholar
• Levine AM, Tulpule A, Espina B et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin’s lymphoma: results of therapy and correlates of response. J. Clin. Oncol.22(13), 2662–2670 (2004).
   PubMed Web of Science ®Google Scholar
• Tulpule A, Sherrod A, Dharmapala D et al. Multidrug resistance (MDR-1) expression in AIDS related lymphomas. Leuk. Res.26, 121–127 (2002).
   PubMed Web of Science ®Google Scholar
• Rahman A, Husain SR, Siddiqui J et al. Liposome mediated modulation of multidrug resistance in human HL-60 leukemia cells. J. Natl Cancer Inst.84, 1909–1915 (1992).
   PubMed Web of Science ®Google Scholar
• Thierry AR, Vige D, Coughlin SS et al. Modulation of doxorubicin resistance in multidrug resistant cells by liposomes. FASEB J.7, 572–579 (1993).
   PubMed Web of Science ®Google Scholar
• Tulpule A, Espina BM, Berman N et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. Clin. Lymphoma Myeloma7(1), 59–64 (2006).
   PubMedGoogle Scholar
• Rigacci L, Mappa S, Nassi L et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol. Oncol.25(4), 198–203 (2007).
   PubMed Web of Science ®Google Scholar
• Visani G, Ferrara F, Alesiani F et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk. Lymphoma49(6), 1081–1086 (2008).
   PubMed Web of Science ®Google Scholar
• Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist5(3), 224–237 (2000)
   PubMedGoogle Scholar
• Herrero J, Gomez-Codina J, Provencio M et al. First efficacy assessment of a Phase II study with cyclophosphamide, vincristine, liposomal doxorubicin, and prednisone plus rituximab, administered every two weeks (R-COMP-14) as primary treatment for NHL. J. Clin. Oncol.25(Suppl. 18) (2007) (ASCO Meeting Abstracts 18519) .
   PubMedGoogle Scholar
• Iannitto E, Luminari S, Mammi C et al. Non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) as initial treatment for patients with splenic marginal zone lymphoma (SMZL). A GISL study. Blood110(11), A1293 (2007).
   Google Scholar
• Dando TM, Keating GM. Liposomal doxorubicin: a review of its use in metastatic breast cancer and potential in non-Hodgkin lymphoma. Am. J. Cancer4(3), 193–206 (2005).
   Google Scholar